VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
Status:
Recruiting
Trial end date:
2023-12-11
Target enrollment:
Participant gender:
Summary
This is a study to understand if taking VTX958 daily orally is safe and effective in
participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients
will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo.
The study consists of a 30-day Screening Period (to see if a participant qualifies for the
study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C,
Dose D, or placebo), and a 4-week Follow-Up Period. The maximal duration of treatment will be
4 months